Global Branded Generics Market, By Product Type (Value-Added Branded Generics, Trade Named Generics), Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-Inflammatory, Others), Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptic, Others), Consumption Type (Oral, Parenteral, Topical, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
The global branded generics market has seen a tremendous increase in demand in recent years. Several intrinsic and extrinsic dynamics relating to licensing, manufacturing, and sales characterize the pharmaceutical industry. The principle of patenting is extremely valuable in the pharmaceutical industry. Drugs that are patented to a specific entity grant that entity legal rights to sell the product in the pharmaceutical industry. Furthermore, pharma companies can avoid being harmed by the presence of several competitors in the market by patenting their products.
- Data Bridge Market Research analyses that the branded generics market was valued at USD 292.3 billion in 2021 and is expected to reach USD 542.28 billion by 2029, registering a CAGR of 8.03% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Branded generics are medicines or pharmaceutical drugs that have been re-released on the market under a different brand name. These are re-released at a lesser cost, and the shape, size, colour, and flavour may differ, even though the medication remains the same. This is due to the fact that the medicine's or pharmaceutical drug's patent has expired. Drugs that can be used to treat hypertension, diabetes, back pain, thyroid, and arthritis, among other conditions, are re-released at cheaper costs in order to stay in the market and survive competition. However, it is important to highlight that, despite the alterations made in the re-release of the drug, the quality remains the same. The functions that the medicine would accomplish are not compromised in any way.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Value-Added Branded Generics, Trade Named Generics), Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-Inflammatory, Others), Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptic, Others), Consumption Type (Oral, Parenteral, Topical, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Abbott (U.S.), Allergan (Ireland), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Novartis AG (Switzerland), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Zydus Cadila (Ahmedabad), Dr. Reddy's Laboratories Ltd. (Hyderabad), Apotex Inc. (Canada)
|
Branded Generics Market Dynamics
Drivers
-
Increasing prevalence rate of chronic diseases will drive the market's growth rate
The rising prevalence rate of chronic diseases and acute ailments will propel the growth rate of branded generics market during the forecast period. Along with this growing number of cancer cases will enhance the demand for branded generics. This will further influence the market dynamics.
-
Rising number of expired patents will flourish the market's growth rate
The rising number of expired patents will flourish the growth rate of branded generics market forward.
Additionally, the rising number of government initiatives to spread awareness among people will majorly influence the branded generics market's growth rate. Other significant factors resulting in the expansion of the market are the rising number of cases of trauma and accident globally and improving healthcare infrastructure. Furthermore, the rising geriatric population and favorable reimbursement policies are the major drivers that will enhance the growth of market.
Opportunities
-
Growth in R&D activities
The rise in the number of research and development activities will provide beneficial opportunities for the branded generics market growth. Along with this, expansion and modernization of healthcare infrastructure across emerging economies will enhance the market's growth rate in coming years.
Moreover, technological advancement and emerging new markets will further expand the branded generics market's growth rate in the future.
Restraints/Challenges
On the other hand, entry of new market players and changing medicine practices will obstruct the market growth. Also, strict regulatory policies and huge competition from branded drugs will pose a major challenge for branded generics market. However, emergence of unfavourable conditions due to COVID-19 outbreak and lack of awareness will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This branded generics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the branded generics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Branded Generics Market
The impact of COVID-19 has generated an opportunity for a large number of patients, as there is a high risk of COVID-19 having negative health impacts on people. COVID-19 has raised demand for APIs and pharmaceuticals; the most in demand are those used to treat malaria, followed by bronchodilators, antibiotics, and antivirals. Sedatives, analgesics, anaesthetics, and muscle relaxants, which are used to care for patients on ventilators, are experiencing a second wave of deficiency. Because of the chronic shortage, the demand for generic medications has surged, resulting in faster FDA approval and the removal of current import warnings.
Global Branded Generics Market Scope
The branded generics market is segmented on the basis of product type, therapeutic application, drug class, consumption type and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Value-Added Branded Generics
- Trade Named Generics
On the basis of product type, the branded generics are segmented into value-added branded generics and trade named generics.
Therapeutic Application
- Oncology
- Cardiovascular Diseases
- Diabetes
- Neurology
- Gastrointestinal Diseases
- Dermatology Diseases
- Analgesics and Anti-Inflammatory
- Others
On the basis of therapeutic application, the branded generics market is segmented into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, analgesics and anti-inflammatory and others.
Drug Class
- Alkylating Agents
- Antimetabolites
- Hormones
- Anti-Hypertensive
- Lipid Lowering Drugs
- Anti-Depressants
- Anti-Psychotics
- Anti-Epileptic
- Others
On the basis of drug class, the branded generics market is segmented into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic and others.
Consumption Type
- Oral
- Parenteral
- Topical
- Others
On the basis of consumption type, the branded generics market is segmented into oral, parental, topical and others.
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
The branded generics market is also segmented on the basis of distribution channel into hospital pharmacies, retail pharmacies, online pharmacies and others.
Branded Generics Market Regional Analysis/Insights
The Branded generics market is analysed and market size insights and trends are provided by country, product type, therapeutic application, drug class, consumption type and distribution channel as referenced above.
The countries covered in the Branded generics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the branded generics market because of the increasing demand and adoption of branded generics across this region. Additionally, the availability of well-developed healthcare facilities will further enhance the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to rising demand for cost-effective medical or pharmaceutical drugs in this region. Also, the growing government funding will propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The branded generics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for branded generics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the branded generics market. The data is available for historic period 2010-2020.
Competitive Landscape and Branded Generics Market Share Analysis
The Branded generics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to branded generics market.
Some of the major players operating in the branded generics market are Abbott (U.S.), Allergan (Ireland), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Novartis AG (Switzerland), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Zydus Cadila (Ahmedabad), Dr. Reddy's Laboratories Ltd., (Hyderabad), and Apotex Inc. (Canada), among others.
SKU-